TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06784544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Operational Stressors
Description: Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational Stressors
Description: Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
Study: NCT06783829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4394
Description: SHR4394
Study: NCT06783972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Touching
Description: In the second stage of birth, when the baby's head crowns, the mother is allowed to touch the baby's head as much as she wants and with as many fingers as she wants.
Study: NCT06783504

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION
Description: The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION
Description: The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
Study: NCT06782867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Neurostimulation (RNS)
Description: The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study: NCT06783660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peptide-loaded collagen sponge and collagen gel complex
Description: A piece of peptide-loaded collagen sponge (Regenomer®) and collagen gel complex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen sponge
Description: Type 1 Collagen sponge (Regenomer)
Study: NCT06786676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS-S603
Description: Oral administration of AS-S603 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo tablet
Study: NCT06783491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin (MM)
Description: Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC \>1.5x109/L and platelets \>75x109/L should be ensured prior to Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC \>1.5x109/L and platelets \>75x109/L should be ensured prior to Day 1 of each 14-day cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
Study: NCT06783673

Intervention type: PROCEDURE
Intervention: Upper GIT endoscopy
Description: upper GIT endoscopy of suspected cases and multiple biopsies will be taken for histopathological examination
Study: NCT06787820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The musical intervention conducted at the senior home focused on the development of rhythmic and vocal skills, as well as the creation of educational experiences that promoted the acquisition of these competencies. To achieve this, both conventional percussion instruments, such as claves, tambourines, woodblocks, and triangles, and unconventional elements, such as buckets played with drumsticks, sheets of paper, spoons, ribbons, elastic bands, and a parachute, were used to mark the rhythm during the singing sessions. The selected songs were chosen based on the musical styles mentioned by the participants during the pre-intervention interview. Furthermore, participants were given the opportunity to showcase their progress at the end of the activity, with the aim of sharing these achievements with family and friends at the home.
Study: NCT06785974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Daily 20mg atorvastatin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily Placebo in combination with ICI-therapy
Study: NCT06783465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital therapeutics session
Description: During the digital therapeutics session, the patient performs tasks by handling objects according to instructions displayed by the device. A camera records the task performance, and the system analyzes the task performance.
Study: NCT06787157

Intervention type: OTHER
Intervention: Prediction Model Construction

Intervention type: OTHER
Intervention: Prediction Model Construction
Study: NCT06784596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsulting supported training
Description: Patients in this group will be provided with training the day before surgery, on the morning of surgery and on the day of discharge, and will receive teleconsulting services at the 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th and 12th weeks after discharge. will be given.
Study: NCT06787118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo for a total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo for a total of 12 weeks.
Study: NCT06788106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity aerobic exercise + synchronous music
Description: This group will be intervened under high-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medium-intensity aerobic exercise + synchronous music
Description: This group will be intervened under medium-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-intensity aerobic exercise + synchronous music
Description: This group will be intervened under low-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
Study: NCT06787599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Tele Exercise
Description: The participants in the study group will be given an online personalized exercise program at home in non-peritoneal dialysis (PD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of teleexercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
Study: NCT06787300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stories that Empowered Mother
Description: this intervention is made by resercher for this research.
Study: NCT06787898

Intervention type: OTHER
Group type: OTHER
Intervention: Group R: retrolaminar block performed group
Description: Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®) was injected posterior to each lamina (T9, T10), totalling 20 mL

Intervention type: OTHER
Group type: OTHER
Intervention: Group C - Placebo
Description: Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®)was injected posterior to each lamina (T9, T10), totalling 20 mL.
Study: NCT06784154

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT06786884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paraffin wax
Description: This is the treatment group that will receive exercise and paraffin wax

Intervention type: DEVICE
Group type: OTHER
Intervention: standard of care exercise therapy
Description: This is the group that will only receive exercise therapy and no paraffin wax.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard of care exercise therapy
Description: This is the group that will only receive exercise therapy and no paraffin wax.
Study: NCT06785987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Lidocaine Infusion
Description: Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fentanyl infusion
Description: Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous remifentanil Infusion
Description: Maintained with sevoflurane and continuous remifentanil infusion under dosage: 3-5μg /kg/hr
Study: NCT06785233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Adjustable Intragastric Balloon
Description: Weight Loss with a 12-Month Non-Adjustable Intragastric Balloon is More Effective Compared to a 6-Month Balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA365
Description: endoscopic treatment of overweight and mild obesity using a 12-month non-adjustable intragastric balloon
Study: NCT06788054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradialysis exercise
Description: moderate intensity aerobic and muscular resistance exercise protocol lasting 12 weeks
Study: NCT06787612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Administered per the protocol
Study: NCT05903755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speed dependent treadmill training on moderate speed
Description: Experimental group will receive 14 session of speed dependent treadmill training on moderate speed (3 to 6) for 25 minutes along with strengthening, stretching and range of motion exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: speed dependent treadmill training on slow speed
Description: Control group will receive 14 session of speed dependent treadmill training on slow speed (1 to 2) for 25 min along with physiotherapy.
Study: NCT01089452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/amlodipine
Description: Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine
Description: Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
Study: NCT06787612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Administered per the protocol
Study: NCT06236854

Intervention type: OTHER
Intervention: Delirium assessment (observational, not interventional)
Description: As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.

Intervention type: OTHER
Intervention: Delirium assessment (observational, not interventional)
Description: As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
Study: NCT05013502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: empagliflozin 10mg PO once daily
Study: NCT06787612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubamatamab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Prophylaxis administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Prophylaxis administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Prophylaxis administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Prophylaxis administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Prophylaxis administered per the protocol
Study: NCT06785246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grasshopper dashboard
Description: Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record
Study: NCT06785610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsulase®
Description: Capsulase® supplement daily administration after surgery
Study: NCT06224218

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Port Robotic Surgery
Description: Single port Robotic surgery will remove the whole prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Surgery
Description: Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
Study: NCT06783114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Botulinum Toxin Type A for injection (YY001)
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
Study: NCT06782568

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
Study: NCT06783868

Intervention type: DEVICE
Intervention: Catheter Ablation
Description: Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.

Intervention type: DRUG
Intervention: Market-approved AVNB, OAC and AAD
Description: Used per protocol for the duration of the trial.
Study: NCT06786468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard systemic treatment for advanced lung cancer
Description: Standard systemic treatment for advanced lung cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard systemic treatment for advanced lung cancer
Description: Standard systemic treatment for advanced lung cancer
Study: NCT06787768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Enriched Rehabilitation Gym
Description: The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants attend a minimum of two times per week and can attend daily for the two hour group based circuit class.
Study: NCT06787092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bladder cycling
Description: started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 250 cc of sterile saline for 2 hours.
Study: NCT06787391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotization of Spinal Accessory Nerve To Supra-Scapular in children with OBPP with deficiency of Shoulder External Rotation
Description: Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve in children with OBPP presented with deficiency of Shoulder External Rotation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve
Description: Just to assess clinical outcomes after Neurotization of spinal accessory nerve to Supra-Scapular Nerve in patients with deficiency of Shoulder External Rotation
Study: NCT06787560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: Each subject receive CD7 CAR T-cells by intravenous infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Description: allogeneic hematopoietic stem cell transplantation